Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 7/20 | 0.46 |
| ▸ | ITPR2 | Q14571 | 3/20 | 0.45 |
| ▸ | ITPR1 | Q14643 | 3/20 | 0.45 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.43 |
| ▸ | PPIP5K2 | O43314 | 1/20 | 0.42 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.40 |
| ▸ | TLR4 | O00206 | 1/20 | 0.38 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3086364 | 1.00 | ITPR3 (0.46) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL9000922 | 0.90 | ITPR3 (0.55) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL15134078 | 0.84 | ITPR3 (0.43) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL8498941 | 0.84 | ITPR3 (0.43) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL3078845 | 0.84 | ITPR3 (0.43) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL6388024 | 0.84 | ITPR3 (0.43) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL5667749 | 0.84 | ITPR3 (0.43) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL8845346 | 0.84 | ITPR3 (0.43) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL8844497 | 0.84 | ITPR3 (0.43) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL6389556 | 0.84 | ITPR3 (0.43) | ITPR3ITPR2ITPR1INPPL1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | BIONERIS AB | 2010-10-14 | — | — | US | claimed |
| EP-0730460-B1 | THE USE OF AN ESTER OF INOSITOLTRISPHOSPHATE FOR THE TREATMENT OF INFLAMMATORY CONDITIONS | PERSTORP AB (SE) | 2002-06-12 | — | — | EP | claimed |
| US-5866557-A | REDUCE TISSUE DAMAGE | PERSTORP AB (SE) | 1999-02-02 | — | — | US | claimed |
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | SIRÈN MATTI (FI) | 2016-03-17 | — | — | US | disclosed |
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | BIONERIS AB | 2010-10-14 | — | — | US | disclosed |
| US-20090175924-A1 | COATED STENT | BIONERIS AB (SE) | 2009-07-09 | — | — | US | disclosed |
| EP-1390045-B1 | THE USE OF A COMPOUND WITH A NEGATIVELY CHARGED DOMAIN OF PHOSPHOROUS-CONTAINING RADICALS FOR THE TREATMENT OF RESTENOSIS | BIONERIS AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20050261756-A1 | Coated stent | BIONERIS AB (SE) | 2005-11-24 | — | — | US | disclosed |
| US-20050227946-A1 | METHOD OF TREATING INFLAMMATORY, TISSUE REPAIR AND INFECTIOUS CONDITIONS | PERSTORP AB (SE) | 2005-10-13 | — | — | US | disclosed |
| US-6949517-B1 | Method of treating inflammatory, tissue repair and infectious conditions | SIREN MATTI | 2005-09-27 | — | — | US | disclosed |
| EP-1545643-A1 | COATED STENT | Bioneris AB, (SE) | 2005-06-29 | — | — | EP | disclosed |
| US-20040235799-A1 | Use of a compound with a negatively charged domain of radicals for the treatment of restenosis | BIONERIS AB (SE) | 2004-11-25 | — | — | US | disclosed |
| WO-2004022123-A1 | COATED STENT | BIONERIS AB (SE) | 2004-03-18 | — | — | WO | disclosed |
| US-6632797-B2 | Administering to a mammal a cyclic compound (acyclic, carbocyclic or heterocyclic) substituted by at least three vicinal phosphorus containing radicals for treating angiogenesis in tumor conditions | SIREN MATTI (FI) | 2003-10-14 | — | — | US | disclosed |
| EP-0730459-B1 | THE USE OF AN ESTER OF INOSITOLTRISPHOSPHATE FOR THE PREPARING OF MEDICAMENTS | PERSTORP AB (SE) | 2003-02-12 | — | — | EP | disclosed |
| EP-1216705-A2 | The use of growth factor modulation compounds substituted with three vicinal phosphorus containing radical in the manufacture of a medicament for tissue repair | PERSTORP AB (SE) | 2002-06-26 | — | — | EP | disclosed |
| EP-0730460-B1 | THE USE OF AN ESTER OF INOSITOLTRISPHOSPHATE FOR THE TREATMENT OF INFLAMMATORY CONDITIONS | PERSTORP AB (SE) | 2002-06-12 | — | — | EP | disclosed |
| US-20020065253-A1 | Use of growth factor modulating compounds | SIREN MATTI (FI) | 2002-05-30 | — | — | US | disclosed |
| US-5866557-A | REDUCE TISSUE DAMAGE | PERSTORP AB (SE) | 1999-02-02 | — | — | US | disclosed |
| US-5846957-A | Use of an ester of inositoltrisphosphate for the preparing of medicaments | PERSTORP AB (SE) | 1998-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | PYGM, GYS1, CPT1B | ITPR3 3281/4885ITPR2 3937/4885ITPR1 3918/4885 |
| US-20020065253-A1 | Use of growth factor modulating compounds | HDGF, PGF, FGF2 | ITPR3 1805/4885ITPR2 1570/4885ITPR1 1357/4885 |
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | TTPA, LPO, HADHB | ITPR3 4534/4885ITPR2 4560/4885ITPR1 4377/4885 |
| US-20040235799-A1 | Use of a compound with a negatively charged domain of radicals for the treatment of restenosis | PCNA, OPRK1, OGFR | ITPR3 3145/4885ITPR2 3537/4885ITPR1 3269/4885 |
| US-20090175924-A1 | COATED STENT | PHOSPHO1, SOST, PLCB3 | ITPR3 294/4885ITPR2 432/4885ITPR1 374/4885 |
| US-20050227946-A1 | METHOD OF TREATING INFLAMMATORY, TISSUE REPAIR AND INFECTIOUS CONDITIONS | TNF, TLR2, TPMT | ITPR3 2069/4885ITPR2 1876/4885ITPR1 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.